4SC-201 (Resminostat) and Sorafenib in Advanced Hepatocellular Carcinoma
Completed
4SC AG
Phase 2
The purpose of the study is to determine whether 4SC-201 alone or in combination with
Sorafenib is effective and safe in the treatment of hepatocellular carcinoma in patients
refractory to Sorafenib monotherapy.
Resminostat (4SC-201) in Relapsed or Refractory Hodgkin's Lymphoma
Completed
4SC AG
Phase 2
The purpose of this study is to determine whether Resminostat (4SC-201) is effective and safe
in the treatment of relapsed or refractory Hodgkin's Lymphoma.
4SC-201 (Resminostat) in Advanced Colorectal Carcinoma
Completed
4SC AG
Phase 1/Phase 2
The purpose of this study is to determine the Maximum Tolerated Dose (MTD) of 4SC-201
(Resminostat) in combination with FOLFIRI and whether 4SC-201 (Resminostat) is effective and
safe in combination FOLFIRI versus FOLFIRI alone in the treatment of advanced colorectal
carcinoma.
Resminostat (YHI-1001) in Combination With Sorafenib in Asian Patients With Advanced Hepatocellular Carcinoma (HCC)
Completed
Yakult Honsha Co., LTD
Phase 1/Phase 2
The purpose of this study is to assess efficacy and safety in combination of resminostat and
sorafenib in Asian patients with advanced HCC previously untreated with systemic
chemotherapy.
Resminostat for Maintenance Treatment of Patients With Advanced Stage Mycosis Fungoides (MF) or Sézary Syndrome (SS)
Recruiting
4SC AG
Phase 2
The purpose of this study is to determine whether resminostat will be able to delay or
prevent worsening of disease in patients with advanced stage mycosis fungoides or Sézary
Syndrome that have recently achieved disease control with previous systemic therapy.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
